Date: November 30, 2021
Time: 8:00am (PST), 11:00am (EST)
The DNA Vector Lab at the German Cancer Research Center (DKFZ) has developed Nano-S/MARt (nS/MARt), a novel DNA Vector platform that combines prolonged CAR/TCR expression with minimal disruption of T cell activity. This antibiotic-free, nanovector technology uses scaffold/matrix attachment regions (S/MARs) for DNA vector maintenance and replication and it can be introduced efficiently into primary human T Cells without toxicity. When combined with GMP-compliant MaxCyte Flow Electroporation® and CliniMACS Prodigy™ automated cell processing, nS/MARt enables the production of clinically relevant recombinant CAR or TCR T cells with enhanced anti-tumor activity in a single week.
- Discuss how n/SMART vectors are used to optimize adoptive cell therapies
- Realize the value of coupling GMP-compliant MaxCyte Flow Electroporation® and CliniMACS Prodigy® automated cell processing to produce safer cell therapies
- Summarize the role of MaxCyte ExPERT GTx Flow Electroporation system in rapid, clinical scale T cell production
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.